Silence Therapeutics Plc Expected to Earn FY2022 Earnings of ($0.44) Per Share (NASDAQ:SLN)
Silence Therapeutics Plc Expected to Earn FY2022 Earnings of ($0.44) Per Share (NASDAQ:SLN)
Silence Therapeutics plc (NASDAQ:SLN – Get Rating) – HC Wainwright issued their FY2022 earnings estimates for shares of Silence Therapeutics in a research report issued to clients and investors on Tuesday, December 6th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.44) per share for the year. HC Wainwright has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Silence Therapeutics' current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Silence Therapeutics' Q4 2022 earnings at $0.45 EPS, Q1 2023 earnings at ($0.47) EPS, Q2 2023 earnings at ($0.42) EPS, Q3 2023 earnings at ($0.43) EPS, Q4 2023 earnings at $0.06 EPS, FY2023 earnings at ($1.38) EPS, FY2024 earnings at ($1.63) EPS, FY2025 earnings at ($1.71) EPS and FY2026 earnings at ($1.78) EPS.
沉默治療公司(納斯達克代碼：SLN-GET評級)-HC Wainwright在12月6日星期二發佈給客戶和投資者的一份研究報告中發佈了他們對沉默治療公司股票2022財年收益的預期。HC Wainwright分析師P.Trucchio預計，該公司今年的每股收益將達到0.44美元。HC Wainwright對該股的評級為買入，目標價為80.00美元。對Silence Treeutics目前全年收益的普遍估計為每股1.10美元。HC Wainwright還發布了對Silence Treateutics 2022年第四季度每股收益的預測，2023年第一季度每股收益(0.47美元)，2023年第二季度每股收益(0.42美元)，2023年第三季度每股收益(0.43美元)，2023年第四季度每股收益0.06美元，2023財年每股收益(1.38美元)，2024財年每股收益(1.63美元)，2025財年每股收益(1.71美元)和2026財年每股收益(1.78美元)。
Separately, Chardan Capital reduced their price target on shares of Silence Therapeutics from $33.00 to $29.00 and set a "buy" rating on the stock in a research report on Thursday, November 17th.
另外，查丹資本在11月17日(星期四)的一份研究報告中將Silence Treateutics的股票目標價從33.00美元下調至29.00美元，並對該股設定了“買入”評級。
Silence Therapeutics Trading Down 3.7 %
沉默治療公司股價下跌3.7%
Institutional Inflows and Outflows
機構資金流入和流出
A number of large investors have recently modified their holdings of SLN. Frazier Life Sciences Management L.P. acquired a new stake in shares of Silence Therapeutics in the 1st quarter worth about $16,742,000. Lombard Odier Asset Management Europe Ltd acquired a new stake in shares of Silence Therapeutics in the 1st quarter worth about $29,669,000. Goldman Sachs Group Inc. increased its holdings in shares of Silence Therapeutics by 27.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company's stock worth $18,350,000 after acquiring an additional 205,815 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Silence Therapeutics in the 2nd quarter worth about $136,000. Finally, UBS Oconnor LLC increased its holdings in shares of Silence Therapeutics by 176.4% in the 3rd quarter. UBS Oconnor LLC now owns 79,636 shares of the company's stock worth $786,000 after acquiring an additional 50,820 shares during the period. 72.14% of the stock is currently owned by institutional investors.
一些大型投資者最近調整了對SLN的持股。Frazier生命科學管理公司在第一季度收購了Silence Treeutics的新股份，價值約16,742,000美元。隆巴德·奧迪爾資產管理歐洲有限公司在第一季度收購了Silence Treeutics價值約29,669,000美元的新股份。高盛股份有限公司在第一季度增持了寂靜治療公司的股份27.1%。高盛股份有限公司在此期間增持了205,815股，目前持有該公司965,815股股票，價值18,350,000美元。Citadel Advisors LLC在第二季度收購了Silence Treeutics的新股份，價值約13.6萬美元。最後，UBS Oconnor LLC在第三季度增持了176.4%的Silence Treateutics股票。瑞銀Oconnor LLC目前持有79,636股該公司股票，價值78.6萬美元，在此期間又收購了50,820股。72.14%的股票目前由機構投資者持有。
Silence Therapeutics Company Profile
沉默治療公司簡介
(Get Rating)
(獲取評級)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Silent Treateutics公司是一家生物技術公司，專注於血液學、心血管和其他罕見和代謝適應症的新型核糖核酸(RNA)療法的發現和開發。該公司的平臺包括mRNAi GalNAc寡核甘酸發現平臺，旨在準確靶向肝臟中特定的疾病相關基因。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Silence Therapeutics (SLN)
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- 免費獲取StockNews.com關於沉默治療的研究報告(SLN)
- 為什麼你應該避免Carvana，即使它可以避免破產
- 投資者是否聽到了Spotify下跌趨勢的終結？
- 美聯儲軸心的問題不是是否，而是何時，這是為什麼
- 在MarketBeat All-Access上搜索的前10名股票
- 王室利多的3個股息之王
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《沉默治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Silence Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。